1 MONTELUKAST SODIUM | 440 of 1080 | 1200 prescriptions Less than 1% of all prescriptions | 950 | 380 patients 11% of all patients | < 11 | |
2 VENTOLIN HFA (ALBUTEROL SULFATE) | 280 of 1160 | 1420 prescriptions Less than 1% of all prescriptions | 1050 | 730 patients 20% of all patients | 520 patients 14% of all patients | |
3 PROAIR HFA (ALBUTEROL SULFATE) | 210 of 1110 | 1190 prescriptions Less than 1% of all prescriptions | 880 | 640 patients 18% of all patients | 510 patients 14% of all patients | |
4 SYMBICORT (BUDESONIDE/FORMOTEROL FUMARATE) | 540 of 1110 | 940 prescriptions Less than 1% of all prescriptions | 800 | 440 patients 12% of all patients | < 11 | |
5 PREDNISONE | 260 of 1180 | 1810 prescriptions Less than 1% of all prescriptions | 1250 | 970 patients 27% of all patients | 690 patients 19% of all patients | |
6 BREO ELLIPTA (FLUTICASONE/VILANTEROL) | 530 of 1080 | 900 prescriptions Less than 1% of all prescriptions | 590 | 410 patients 11% of all patients | < 11 | |
7 ADVAIR DISKUS (FLUTICASONE PROPION/SALMETEROL) | 420 of 1050 | 580 prescriptions Less than 1% of all prescriptions | 410 | 210 patients 6% of all patients | < 11 | |
8 OMEPRAZOLE | 150 of 690 | 720 prescriptions Less than 1% of all prescriptions | | 260 patients 7% of all patients | < 11 | |
9 SPIRIVA (TIOTROPIUM BROMIDE) | 430 of 1020 | 540 prescriptions Less than 1% of all prescriptions | 360 | 160 patients 4% of all patients | < 11 | |
10 FLUTICASONE PROPIONATE | 480 of 990 | 380 prescriptions Less than 1% of all prescriptions | 250 | 180 patients 5% of all patients | < 11 | |
11 TRELEGY ELLIPTA (FLUTICASONE/UMECLIDIN/VILANTER) | 190 of 620 | 400 prescriptions Less than 1% of all prescriptions | | 170 patients 5% of all patients | < 11 | |
12 ANORO ELLIPTA (UMECLIDINIUM BRM/VILANTEROL TR) | 610 of 1030 | 400 prescriptions Less than 1% of all prescriptions | | 130 patients 4% of all patients | < 11 | |
13 OFEV (NINTEDANIB ESYLATE) | 70 of 290 | 470 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
14 ADVAIR HFA (FLUTICASONE PROPION/SALMETEROL) | 140 of 550 | 300 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
15 FUROSEMIDE | 240 of 670 | 420 prescriptions Less than 1% of all prescriptions | 420 | 150 patients 4% of all patients | 150 patients 4% of all patients | |
16 AZITHROMYCIN | 210 of 920 | 780 prescriptions Less than 1% of all prescriptions | 610 | 530 patients 15% of all patients | 380 patients 11% of all patients | A |
17 INCRUSE ELLIPTA (UMECLIDINIUM BROMIDE) | 580 of 960 | 260 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
18 ELIQUIS (APIXABAN) | 60 of 200 | 300 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
19 ROPINIROLE HCL | 170 of 310 | 120 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
20 DULERA (MOMETASONE/FORMOTEROL) | 230 of 370 | 110 prescriptions Less than 1% of all prescriptions | 110 | < 11 | < 11 | |
21 SPIRIVA RESPIMAT (TIOTROPIUM BROMIDE) | 660 of 920 | 130 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
22 H.P. ACTHAR (CORTICOTROPIN) | 10 of 30 | 210 prescriptions Less than 1% of all prescriptions | 00 | < 11 | 00 patients Less than 1% of all patients | |
23 DYMISTA (AZELASTINE/FLUTICASONE) | 120 of 170 | 110 prescriptions Less than 1% of all prescriptions | 110 | < 11 | < 11 | |
24 AMLODIPINE BESYLATE | 140 of 180 | 120 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
25 PROVIGIL (MODAFINIL) | 10 | 120 prescriptions Less than 1% of all prescriptions | 120 | < 11 | < 11 | |
26 PROMETHAZINE HCL | 40 of 90 | 270 prescriptions Less than 1% of all prescriptions | 120 | 160 patients 4% of all patients | < 11 | |
27 NYSTATIN | 100 of 190 | 150 prescriptions Less than 1% of all prescriptions | | < 11 | < 11 | |
28 AMOXICILLIN-CLAVULANATE POTASS (AMOXICILLIN/POTASSIUM CLAV) | 230 of 360 | 140 prescriptions Less than 1% of all prescriptions | | 140 patients 4% of all patients | < 11 | A |
29 LEVOFLOXACIN | 270 of 580 | 170 prescriptions Less than 1% of all prescriptions | | 150 patients 4% of all patients | < 11 | A |